Hydrocortison Hoechst® . (Hydrocortisone)

Hydrocortison Hoechst® is indicated for several medical conditions where replacement of cortisol or suppression of inflammation is required. It is commonly employed in endocrine, dermatologic, and allergic contexts under physician guidance.

• Primary adrenal insufficiency (Addison’s disease) requiring cortisol replacement.
• Congenital adrenal hyperplasia with glucocorticoid deficiency.
• Acute or chronic inflammatory disorders such as arthritis, ulcerative colitis, or asthma exacerbations.
• Severe allergic reactions, including drug‑induced or contact dermatitis.
• Autoimmune conditions where immunosuppression is needed, e.g., systemic lupus erythematosus.

• Hydrocortison Hoechst® works by binding to intracellular glucocorticoid receptors, forming a complex that translocates to the nucleus and modulates gene transcription. This interaction up‑regulates anti‑inflammatory proteins such as annexin‑1 and down‑regulates pro‑inflammatory cytokines, chemokines, and adhesion molecules. The net effect reduces leukocyte migration, capillary permeability, and immune cell activation, thereby providing both glucocorticoid replacement and anti‑inflammatory actions.

Adverse reactions to Hydrocortison Hoechst® can vary in frequency and severity.

Common

• Increased appetite or weight gain.
• Mild mood changes or insomnia.
• Elevated blood glucose levels.

Serious

• Severe hypertension or fluid retention.
• Osteoporosis with increased fracture risk.
• Suppressed adrenal axis leading to adrenal crisis if stopped abruptly.

When prescribing or taking Hydrocortison Hoechst®, several safety considerations should be observed.

• Do not use in patients with systemic fungal infections without appropriate antifungal coverage.
• Monitor blood pressure, glucose, and electrolytes regularly during therapy.
• Taper the dose gradually when discontinuing to avoid adrenal insufficiency.
• Use with caution in pregnant or breastfeeding women; benefits must outweigh potential risks.
• Assess for history of psychiatric disorders, as glucocorticoids may exacerbate symptoms.
• Avoid in patients with known hypersensitivity to hydrocortisone or excipients.

Hydrocortison Hoechst® may interact with other medicines, influencing its effectiveness or safety.

Avoid

• Concurrent use with potent CYP3A4 inducers (e.g., rifampin, phenytoin) may reduce efficacy.
• Combined therapy with other systemic glucocorticoids can increase risk of systemic toxicity.

Use with caution

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) may raise risk of gastrointestinal bleeding.
• Anticoagulants (warfarin) may have enhanced anticoagulant effect.
• Vaccines containing live attenuated organisms may have reduced efficacy.
• Diuretics may potentiate fluid‑retention effects.